Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

Contributed by: GlobeNewswire

Tags

Charing Cross

More Like This

PR Newswire associated0

Terumo Neuro Launches Aneurysm Treatment Alliance in EMEA to Advance Physician Collaboration and Aneurysm Care

PR Newswire associated0

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

PR Newswire associated0

Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

PR Newswire associated0

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with First-in-Human Success

PR Newswire associated0

ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH

Business Wire logo

Rapid Medical™ Announces Japanese Approval and Exclusive Partnership With Kaneka for TIGERTRIEVER–The World’s Only Adjustable Thrombectomy Device